EP Patent

EP1820862A2 — Medical preparations for the treatment of alpha-galactosidase a deficiency

Assigned to Shire Human Genetics Therapies Inc · Expires 2007-08-22 · 19y expired

What this patent protects

The invention provides highly purified α-Gal A, and various methods for purifying it; α-Gal A preparations with altered charge and methods for making those preparations; α-Gal A preparations that have an extended circulating half-life in a mammalian host, and methods for making s…

USPTO Abstract

The invention provides highly purified α-Gal A, and various methods for purifying it; α-Gal A preparations with altered charge and methods for making those preparations; α-Gal A preparations that have an extended circulating half-life in a mammalian host, and methods for making same; and methods and dosages for administering an α-Gal A preparation to a subject.

Drugs covered by this patent

Patent Metadata

Patent number
EP1820862A2
Jurisdiction
EP
Classification
—
Expires
2007-08-22
Drug substance claim
No
Drug product claim
No
Assignee
Shire Human Genetics Therapies Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.